Oppenheimer Remains Bullish on Imperva (IMPV) Following a Disappointing 2Q Pre-Announcement

Evercore ISI Starts Imperva (IMPV) at Hold

Evercore ISI initiated coverage on Imperva (NYSE: IMPV) with a Hold rating and a price target of $45.

For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.

Shares of Imperva closed at $45.64 yesterday.

Imperial Capital Reiterates Outperform on Imperva (IMPV) Following 2Q Preliminary Results

Imperial Capital reiterated an Outperform rating and $55.00 price target on Imperva (NYSE: IMPV) following the company's 2Q preliminary results. IMPV reported preliminary revenue of $57.5-58.0mn and adjusted net loss per share of ($0.20)-
($0.22). Results came in below Street revenue estimates of... More

Nomura Securities Cuts Price Target on Imperva (IMPV) Following Preliminary 2Q Results

Nomura Securities maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $55.00 (from $60.00), following the company's preliminary 2Q financial results. IMPV is expecting revenue to be in the range of $57.5-58.0mn, an 8% growth yoy. This is down from the previous revenue... More

Deutsche Bank Downgrades Imperva (IMPV) to Hold

Deutsche Bank downgraded Imperva (NYSE: IMPV) from Buy to Hold with a price target of $43.00 (from $45.00). The change follow disappointing preliminary Q2 results.

"IMPV negatively pre-announced its Q216 numbers, and blamed longer sales cycles and smaller deals sizes for the weakness in... More

Imperva (IMPV): Previews a Miss for June Qtr - Needham

Imperva (NYSE: IMPV) negatively preannounced F2Q16 with lower than expected revenue and a wider loss than anticipated. Needham analyst, Scott Zeller, downgraded IMPV following the MarQ (5/6/16), after it guided below consensus for June and projected a back-end loaded CY16. The analyst's concerns were... More

After-Hours Stock Movers 07/11: (STX) (BDSI) (AA) Higher; (CYTR) (IMPV) (VOXX) Lower (more...)

Today's After-Hours Movers

CytRx Corporation (NASDAQ: CYTR) 64% LOWER; announced the results of an analysis of its global, randomized, Phase 3 clinical trial of aldoxorubicin compared to investigator's choice therapy in patients with relapsed or refractory soft tissue sarcomas (STS).... For the current evaluation, the study did not show a significant difference between aldoxorubicin and investigator's choice therapy for PFS, with a median of 4.17 months and 4.04 months, respectively, for the study's primary endpoint (hazard ratio: 0.91).

Seagate Technology plc (NASDAQ: STX) 13.2% HIGHER;... More

Imperva (IMPV) Issues Q2 Profit Warning

Imperva, Inc. (NYSE: IMPV), committed to protecting business-critical data and applications in the cloud and on-premises, today announced preliminary financial results for the second quarter ended June 30, 2016.

Based on preliminary financial information, Imperva currently expects to report total revenue for the second quarter of 2016 in the range of $57.5 million to $58.0... More

Imperva (IMPV) Min. Price Seen at $55-$65/Share - BTIG

BTIG maintained a Buy rating on Imperva (NYSE: IMPV) with a price target of $55. Analyst Joel P. Fishbein thinks asset sales appear likely in today's robust M&A environment.

"Reuters reported that Imperva was interviewing investment banks for help in exploring strategic options after... More

Pre-Open Stock Movers 07/11: (BLFS) (SGNT) (IMPV) Higher; (CJES) (TWTR) (CHTR) Lower (more...)

Today's Pre-Open Stock Movers:

BioLife Solutions (NASDAQ: BLFS) 112% HIGHER; announced that it has entered into a ten year supply agreement with Kite Pharma (Nasdaq: KITE), a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) 39.6% HIGHER; Nichi-Iko Pharmaceutical Co., Ltd and Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced that they have entered into a definitive... More

Imperva (IMPV) Gains as Elliott Presses Company to Explore a Sale

Imperva (NYSE: IMPV) is gaining modestly (+2%) in pre-open trade Monday following reports late Friday from Reuters the company has hired an investment bank to help it explore strategic options amid pressure from activist hedge fund Elliott Management, citing people familiar with the... More

Option volume flows

Stocks and options expected to be active: IMPV WMT AMZN KMI SO AET HUM NFLX TSLA

Notable call activity cited July 8; BID TV BHI YRCW R CERS TSL PODD CUDA

Notable put activity cited July 8; JUNO AVG RDSB PAYX AER DD SONC HRTX

Exclusive: Imperva seeks investment bank to explore options - sources

By Liana B. Baker

(Reuters) - U.S. cyber security company Imperva Inc (NYSE: IMPV) is seeking to hire an investment bank to help it explore strategic options after coming under pressure from activist hedge fund Elliott Management Corp, according to people familiar with the matter.

The move comes after Elliott unveiled a nearly 10 percent stake in Imperva last month and argued its shares are undervalued. Elliott said in a regulatory filing it was speaking to the company about "strategic and operational opportunities."

Imperva could appoint a financial adviser as... More

Macquarie Starts Imperva (IMPV) at Neutral

Macquarie initiated coverage on Imperva (NYSE: IMPV) with a Neutral rating and a price target of $46.00.

For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.

Shares of Imperva closed at $43.54 yesterday.